GleamWall
中文EN

XERS Xeris Biopharma Holdings, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1867096 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY38.4%
TTM net income YoY58.5%
TTM EPS YoY70.0%
Revenue 3-yr CAGR34.1%
Net income 3-yr CAGR—

Margins

Gross margin87.4%
Operating margin12.7%
Net margin-1.8%
FCF margin—
EBITDA margin13.1%

Returns

ROE-27.1%
ROA-1.6%
ROIC (approx.)31.5%
Asset turnover0.93x

Leverage & solvency

Liabilities / assets88.5%
Debt / equity3.89x
Current ratio2.15x
Interest coverage1.70x

Cash quality & payout

Operating cash flow / net income-11.34x
Accruals ratio-20.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$291.85M$203.07M
Cost of revenue$42.57M$36.83M
Gross profit$249.28M$166.24M
R&D expense$31.16M$25.56M
SG&A expense$182.37M$163.48M
Operating income$24.90M-$33.65M
Interest expense$29.08M$30.48M
Pretax income$554,000-$57.10M
Income tax$0-$2.27M
Net income$554,000-$54.84M
EBITDA$26.21M-$32.42M
EPS (basic)0.00-0.37
EPS (diluted)0.00-0.37
Weighted avg. shares (diluted)172.74M146.77M
Balance sheet
Cash & equivalents$111.04M$75.74M
Short-term investments—$0
Receivables$51.05M$40.41M
Inventory$68.67M$48.17M
Current assets$240.31M$167.66M
PP&E, net$4.95M$5.56M
Goodwill$22.86M$22.86M
Intangibles$88.08M$98.92M
Total assets$383.53M$323.06M
Current liabilities$109.57M$100.44M
Short-term debt$0$15.10M
Long-term debt$220.34M$217.01M
Total debt$220.34M$232.11M
Total liabilities$369.84M$352.68M
Shareholders' equity$13.69M-$29.61M
Net debt$109.29M$156.36M
Shares outstanding166.22M149.43M
Cash flow statement
Operating cash flow$28.63M-$36.98M
Investing cash flow-$696,000$4.88M
Financing cash flow$11.39M$36.17M
Depreciation & amortization$1.31M$1.23M
Stock-based compensation$22.37M$18.36M

Free plan shows the latest 2 periods; Pro shows all 6 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.